Seymour JF, Kipps TJ, Eichhorst BF, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. ASH 59th Annual Meeting & Exhibition, abstract LBA-2.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie